Company Information

ZYDUS LIFESCIENCES LTD.

NSE : ZYDUSLIFEBSE : 532321ISIN CODE : INE010B01027Industry : Pharmaceuticals & DrugsHouse : Cadila
BSE937.55-7.6 (-0.8 %)
PREV CLOSE ( ) 945.15
OPEN PRICE ( ) 956.55
BID PRICE (QTY) 936.85 (22)
OFFER PRICE (QTY) 937.35 (38)
VOLUME 17473
TODAY'S LOW / HIGH ( )935.00 956.55
52 WK LOW / HIGH ( )482.55 1031.3
NSE936.40-8.45 (-0.89 %)
PREV CLOSE( ) 944.85
OPEN PRICE ( ) 954.80
BID PRICE (QTY) 936.35 (3)
OFFER PRICE (QTY) 936.55 (12)
VOLUME 238228
TODAY'S LOW / HIGH( ) 934.80 954.80
52 WK LOW / HIGH ( )484.95 1031.7
ChairmanPankaj R Patel
Managing DirectorSharvil P Patel
Company SecretaryDhaval N Soni
Executive DirectorGanesh N Nayak
Non Executive DirectorMukesh M Patel
Non Executive Independent DirectorNitin R Desai
Bhadresh K Shah
Dharmishta N Raval
Apurva S Diwanji
Akhil Monappa
Upasana Konidela
Incorporation Year : 15-05 1995

Registered Office :

Address : Zydus Corporate Park, Scheme No.63,Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,Sarkhej - Gandhinagar Highway Ahmedabad,
Gujarat-382481 .

Phone : 079-71800000 / 48040000

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,MCX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.